Palopegteriparatide

The majority of adults with hypoparathyroidism achieved normal serum calcium levels with palopegteriparatide at 1 year without supplemental vitamin D or calcium, according to data from a phase 3 open-label extension.

Beginning in 2026, prices for 10 drugs will be reduced for Medicare Part D recipients, according to a CMS press release.

A parathyroid hormone prodrug developed to treat hypoparathyroidism received FDA approval, according to an industry press release.

The FDA has rejected a new drug application for an agent to treat adults with hypoparathyroidism due to concerns with manufacturing control strategy, according to an industry press release.